Goal Directed Medical Therapies for Patients with Diabetic Kidney Disease

Leading experts in the care of individuals with diabetic kidney disease (DKD) describe what is the new standard of care for DKD, discuss the clinical indications for SGLT2 inhibitors, and consider payment issues associated with new therapies. The presentation concludes with a roundtable discussion of key questions, including those submitted by the videoconference participants.